Takeda And Cell Genesys Ink $270 Million Development Deal for GVAX Immunotherapy
PERTH, Australia - Japan-based Takeda and San Francisco-based Cell Genesys formed a global development alliance for Cell Genesys's lead product GVAX immunotherapy for prostate cancer, currently in Phase III trials